{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.8","upperLimit":"1.9","value":"1.9"},{"groupId":"OG001","lowerLimit":"1.5","upperLimit":"2.0","value":"1.9"}]}],"title":"6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.8","upperLimit":"1.9","value":"1.9"},{"groupId":"OG001","lowerLimit":"1.6","upperLimit":"2.1","value":"1.9"}]}],"title":"2 Years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"306"},{"groupId":"OG001","value":"305"}],"units":"Participants"}],"description":"A participants' time to MaHR was defined as the time from the first dosing date until criteria are first met for CHR or NEL, whichever occurred first. Non-responders were censored at the maximum of the date of last hematologic or cytogenetic assessment. Median time was measured in months.","dispersionType":"95% Confidence Interval","groups":[{"description":"Dasatinib was administered orally at a dose of 140 mg once a day (QD) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant.","id":"OG000","title":"Dasatinib 140 mg QD"},{"description":"Dasatinib was administered orally at a dose of 70 mg twice a day (BID) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant..","id":"OG001","title":"Dasatinib 70 mg BID"}],"paramType":"MEDIAN","populationDescription":"Participants were analyzed based on the treatment they were randomized to receive.","reportingStatus":"POSTED","timeFrame":"Day 1 up to 6 months (time of primary endpoint), 2 years","title":"Median Time to Major Hematologic Response (MaHR) - Randomized Population","type":"SECONDARY","unitOfMeasure":"Months"}